Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

Deborah L. Darrington; Julie M. Vose; James R. Anderson; Philip J. Bierman; Michael R. Bishop; Wing C. Chan; Mary E. Morris; Elizabeth C. Reed; Warren G. Sanger; Stefano R. Tarantolo; Dennis D. Weisenburger; Anne Kessinger; James O. Armitage

doi:10.1200/JCO.1994.12.12.2527

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

Deborah L. Darrington, Julie M. Vose, James R. Anderson, Philip J. Bierman, Michael R. Bishop, Wing C. Chan, Mary E. Morris, Elizabeth C. Reed, Warren G. Sanger, Stefano R. Tarantolo, Dennis D. Weisenburger, Anne Kessinger, James O. Armitage

Research output: Contribution to journal › Article › peer-review

329 Scopus citations

Abstract

Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

Original language	English (US)
Pages (from-to)	2527-2534
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	12
Issue number	12
DOIs	https://doi.org/10.1200/JCO.1994.12.12.2527
State	Published - Dec 1994

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.1994.12.12.2527

Fingerprint

Dive into the research topics of 'Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies'. Together they form a unique fingerprint.

Cite this

Darrington, D. L., Vose, J. M., Anderson, J. R., Bierman, P. J., Bishop, M. R., Chan, W. C., Morris, M. E., Reed, E. C., Sanger, W. G., Tarantolo, S. R., Weisenburger, D. D., Kessinger, A., & Armitage, J. O. (1994). Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology, 12(12), 2527-2534. https://doi.org/10.1200/JCO.1994.12.12.2527

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. / Darrington, Deborah L.; Vose, Julie M.; Anderson, James R. et al.
In: Journal of Clinical Oncology, Vol. 12, No. 12, 12.1994, p. 2527-2534.

Research output: Contribution to journal › Article › peer-review

Darrington, DL, Vose, JM, Anderson, JR, Bierman, PJ, Bishop, MR, Chan, WC, Morris, ME, Reed, EC, Sanger, WG, Tarantolo, SR, Weisenburger, DD, Kessinger, A & Armitage, JO 1994, 'Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies', Journal of Clinical Oncology, vol. 12, no. 12, pp. 2527-2534. https://doi.org/10.1200/JCO.1994.12.12.2527

Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology. 1994 Dec;12(12):2527-2534. doi: 10.1200/JCO.1994.12.12.2527

@article{0ec1897a4a654cf9a06d0aa3cf6225e5,

title = "Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies",

abstract = "Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.",

author = "Darrington, {Deborah L.} and Vose, {Julie M.} and Anderson, {James R.} and Bierman, {Philip J.} and Bishop, {Michael R.} and Chan, {Wing C.} and Morris, {Mary E.} and Reed, {Elizabeth C.} and Sanger, {Warren G.} and Tarantolo, {Stefano R.} and Weisenburger, {Dennis D.} and Anne Kessinger and Armitage, {James O.}",

year = "1994",

month = dec,

doi = "10.1200/JCO.1994.12.12.2527",

language = "English (US)",

volume = "12",

pages = "2527--2534",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "12",

}

TY - JOUR

T1 - Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

AU - Darrington, Deborah L.

AU - Vose, Julie M.

AU - Anderson, James R.

AU - Bierman, Philip J.

AU - Bishop, Michael R.

AU - Chan, Wing C.

AU - Morris, Mary E.

AU - Reed, Elizabeth C.

AU - Sanger, Warren G.

AU - Tarantolo, Stefano R.

AU - Weisenburger, Dennis D.

AU - Kessinger, Anne

AU - Armitage, James O.

PY - 1994/12

Y1 - 1994/12

N2 - Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

AB - Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

UR - http://www.scopus.com/inward/record.url?scp=0028110040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028110040&partnerID=8YFLogxK

U2 - 10.1200/JCO.1994.12.12.2527

DO - 10.1200/JCO.1994.12.12.2527

M3 - Article

C2 - 7989926

AN - SCOPUS:0028110040

SN - 0732-183X

VL - 12

SP - 2527

EP - 2534

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 12

ER -

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this